SU1455999A3 - Способ получени дигиталис-антител - Google Patents

Способ получени дигиталис-антител Download PDF

Info

Publication number
SU1455999A3
SU1455999A3 SU843817568A SU3817568A SU1455999A3 SU 1455999 A3 SU1455999 A3 SU 1455999A3 SU 843817568 A SU843817568 A SU 843817568A SU 3817568 A SU3817568 A SU 3817568A SU 1455999 A3 SU1455999 A3 SU 1455999A3
Authority
SU
USSR - Soviet Union
Prior art keywords
antibodies
digitalis
graduate
buffer
papain
Prior art date
Application number
SU843817568A
Other languages
English (en)
Russian (ru)
Inventor
Бац Ханс-Георг
Юнгфер Херберт
Ленц Хельмут
Бедер Альберт
Original Assignee
Берингер Маннхайм Гмбх (Фирма)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Берингер Маннхайм Гмбх (Фирма) filed Critical Берингер Маннхайм Гмбх (Фирма)
Application granted granted Critical
Publication of SU1455999A3 publication Critical patent/SU1455999A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SU843817568A 1983-11-26 1984-11-23 Способ получени дигиталис-антител SU1455999A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833342870 DE3342870A1 (de) 1983-11-26 1983-11-26 Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen

Publications (1)

Publication Number Publication Date
SU1455999A3 true SU1455999A3 (ru) 1989-01-30

Family

ID=6215371

Family Applications (1)

Application Number Title Priority Date Filing Date
SU843817568A SU1455999A3 (ru) 1983-11-26 1984-11-23 Способ получени дигиталис-антител

Country Status (8)

Country Link
US (1) US4742159A (https=)
EP (1) EP0143413B1 (https=)
JP (1) JPS60132922A (https=)
AT (1) ATE64141T1 (https=)
CA (1) CA1242393A (https=)
DE (2) DE3342870A1 (https=)
ES (1) ES8600770A1 (https=)
SU (1) SU1455999A3 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849352A (en) 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
US4841024A (en) * 1986-09-15 1989-06-20 Becton Dickinson And Company Purification of antibodies
US4814433A (en) * 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
JPH0623761B2 (ja) * 1988-12-09 1994-03-30 株式会社ピーシーシーテクノロジー 配糖化した化合物を生産する細胞の検出方法
US5328834A (en) * 1989-09-08 1994-07-12 Unisyn Technologies, Inc. Method for preparing immunoglobulin fragments
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
EP1293221A4 (en) * 2000-05-25 2009-02-25 Kaneka Corp CARDIAC GLYCOSIDE ADSORBENT AND METHOD AND DEVICE FOR ADSORPTION AND REMOVAL OF CARDIAC GLYCOSIDE
FR2810667B1 (fr) * 2000-06-23 2004-09-03 Warner Lambert Co Procede d'isolement et de purification d'une proteine, et proteine obtenue
US6987079B2 (en) * 2001-08-14 2006-01-17 W.R. Grace & Co.-Conn. Supported catalyst systems
US6802966B2 (en) 2001-08-14 2004-10-12 W. R. Grace & Co. Conn. Solid compositions for selective adsorption from complex mixtures
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
CA2656347A1 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
WO2010065437A1 (en) 2008-12-03 2010-06-10 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
HUE039009T2 (hu) 2011-08-05 2018-12-28 Res Found Dev Javított eljárások és készítmények Olfml3-mediált angiogenesis modulálására
WO2014066590A1 (en) 2012-10-24 2014-05-01 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
CA2921652A1 (en) 2013-08-21 2015-02-26 Manuel A. Riquelme Compositions and methods for targeting connexin hemichannels
EP3383911B1 (en) 2015-12-02 2021-01-20 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
EP3419998A4 (en) 2016-02-26 2019-09-25 The Board of Regents of The University of Texas System CONNEXIN (CX) 43 HEMICANAL BINDING ANTIBODIES AND USES THEREOF
ES2883297T3 (es) 2016-03-29 2021-12-07 Stcube Inc Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos
EP3436480A4 (en) 2016-03-30 2019-11-27 Musc Foundation for Research Development METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
CN109715666B (zh) 2016-07-20 2023-02-21 斯特库比股份有限公司 癌症治疗方法和使用结合糖基化pd-l1的抗体的组合的疗法
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
KR20200026209A (ko) 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
DE112018005145T5 (de) 2017-09-15 2020-07-23 The Regents Of The University Of California Hemmung von aminoacylase 3 (aa3) bei der behandlung von krebs
CN111868039A (zh) 2017-09-26 2020-10-30 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
WO2019236590A1 (en) 2018-06-04 2019-12-12 University Of Maryland, Baltimore Methods for preventing acute kidney injury
US20220411511A1 (en) 2019-09-26 2022-12-29 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
EP4041768A1 (en) 2019-10-09 2022-08-17 StCube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
CA3168337A1 (en) 2020-02-17 2021-08-26 Marie-Andree Forget Methods for expansion of tumor infiltrating lymphocytes and use thereof
WO2023056361A1 (en) 2021-09-29 2023-04-06 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof
CN113736744B (zh) * 2021-10-14 2023-07-18 江南大学 洋地黄毒苷单克隆抗体杂交瘤细胞株及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790475A (en) * 1972-03-27 1974-02-05 Corning Glass Works Porous glass support material
US4039652A (en) * 1973-10-11 1977-08-02 Miles Laboratories, Inc. Column method of immunoassay employing an immobilized binding partner
US4081245A (en) * 1976-05-03 1978-03-28 Beckman Instruments, Inc. Immunoassay procedure employing novel immunochemical composites
US4081246A (en) * 1976-05-03 1978-03-28 Beckman Instruments, Inc. Solid phase column immunoassay procedure employing novel immunochemical composites
US4232004A (en) * 1977-09-21 1980-11-04 American National Red Cross Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification therewith
US4434234A (en) * 1981-04-02 1984-02-28 The Upjohn Company Method and kit for silver staining substances supported in matrix

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ргос. Nat.Acad. Sci. US. 1971, r. 68, p. 2401-2406. *

Also Published As

Publication number Publication date
ES537909A0 (es) 1985-11-01
DE3342870A1 (de) 1985-06-05
JPH0324480B2 (https=) 1991-04-03
CA1242393A (en) 1988-09-27
ES8600770A1 (es) 1985-11-01
EP0143413B1 (de) 1991-06-05
EP0143413A3 (en) 1988-07-20
ATE64141T1 (de) 1991-06-15
US4742159A (en) 1988-05-03
DE3484673D1 (de) 1991-07-11
JPS60132922A (ja) 1985-07-16
EP0143413A2 (de) 1985-06-05

Similar Documents

Publication Publication Date Title
SU1455999A3 (ru) Способ получени дигиталис-антител
US4606825A (en) Purification of immunoglobulin G
JPS6361318B2 (https=)
JPS59225196A (ja) 組織蛋白質およびその単離法
WO1992003736A1 (fr) Agent de detection de l'endotoxine
US4181713A (en) Isolation of HBs Ag
JPH0428718B2 (https=)
US4302385A (en) Placenta-specific tissue protein PP10
US4468345A (en) Protein (PP17), a process for concentrating and isolating it and its use
US4746731A (en) Isolated tissue protein PP18
US4368148A (en) Protein PP9, process for its enrichment and its isolation and its use
CA1101847A (en) Process for the concentration of a placenta-specific glycoprotein
US4325866A (en) Protein, PP11, a process for its preparation and its use
US4592863A (en) Protein PP20, a process for obtaining it, and its use
US4264449A (en) Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification therewith
US4232004A (en) Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification therewith
Aalberse et al. The purification of human polyclonal IgE by immunosorption
JPS6034916A (ja) 第１ｘ因子および他のビタミンｋ依存性タンパク質の高純度精製
US4594328A (en) Tissue protein PP21, a process for obtaining it and its use
JPS63123395A (ja) 抗ｐｃｉモノクローナル抗体、これを用いた抗ｐｃｉの精製法及び免疫学的測定法
US4656025A (en) Quantitative screening assay of tumor globulin from gastric juice
GB1599435A (en) Glycoprotein and process for its production
RU2325171C1 (ru) Способ выделения и очистки трофобластического бета-1-гликопротеина
MacKAY et al. Quantitative recovery, selective removal and one‐step purification of human parotid and leukemic lysozymes by immunoadsorption
JPS62258399A (ja) Ｃ−反応性蛋白質の精製方法